Hospital
University Hospital of Brooklyn Suny Downstate Health Sciences Univers
University Hospital of Brooklyn Suny Downstate Health Sciences Univers was paid $42.34M by Medicaid between Jan 2018 and Dec 2024, across 424 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoUNIVERSITY HOSPITAL OF BROOKLYN SUNY DOWNSTATE HEALTH SCIENCES UNIVERS
BROOKLYN, NY 11203
BROOKLYN, NY 11203
33aNPI1639179328assigned 07/26/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$42.34M
24GClaims1,066,663
24DCodes billed424
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#36 of 231
Median peer was paid$561K
This provider vs. median75×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,965 | $941K | |
| 2019 | 84,404 | $3.54M | |
| 2020 | 176,605 | $6.77M | |
| 2021 | 224,018 | $8.32M | |
| 2022 | 203,520 | $7.89M | |
| 2023 | 202,578 | $8.24M | |
| 2024incomplete | 160,573 | $6.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 41,972 | 38,187 | $7.91M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.9% | 22,548 | 20,210 | $3.75M |
| G0378 | Hospital observation service, per hour | 8.4% | 2,629 | 2,541 | $3.57M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 15,575 | 12,546 | $2.10M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.3% | 18,531 | 15,775 | $1.82M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.8% | 19,709 | 16,970 | $1.62M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 5,958 | 5,794 | $1.18M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.3% | 6,018 | 5,433 | $965K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 6,042 | 5,728 | $762K |
| 80053 | Comprehensive metabolic panel | 1.5% | 59,121 | 54,351 | $642K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 5,331 | 4,711 | $457K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 736 | 730 | $448K |
412 more codes
| 59025 | Fetal non-stress test | <1% | 6,356 | $422K |
| 87536 | <1% | 5,202 | $402K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,513 | $398K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,373 | $394K |
| 86480 | <1% | 6,909 | $384K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,311 | $371K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,554 | $361K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 3,797 | $327K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,274 | $299K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,767 | $282K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 3,423 | $277K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12,220 | $273K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,009 | $272K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 11,459 | $268K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,331 | $264K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,287 | $258K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,845 | $257K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 380 | $224K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,115 | $221K |
| 42830 | <1% | 146 | $209K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,880 | $207K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 645 | $202K |
| 86850 | <1% | 10,774 | $201K | |
| 99205 | Prolong outpt/office vis | <1% | 1,497 | $198K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,031 | $194K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,672 | $186K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,738 | $185K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 55,173 | $169K |
| 76801 | <1% | 2,287 | $169K | |
| 86360 | <1% | 3,730 | $167K | |
| 93975 | <1% | 856 | $165K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 2,002 | $164K |
| 92567 | <1% | 3,828 | $159K | |
| 92557 | <1% | 3,587 | $149K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,023 | $145K |
| 90651 | <1% | 1,561 | $139K | |
| 76818 | <1% | 1,884 | $136K | |
| 99443 | <1% | 1,038 | $132K | |
| 67400 | <1% | 96 | $129K | |
| 80061 | Lipid panel | <1% | 16,378 | $123K |
| 90750 | <1% | 1,034 | $122K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,926 | $122K |
| 99442 | <1% | 1,198 | $121K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,669 | $120K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,899 | $115K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 184 | $114K |
| 96367 | <1% | 2,037 | $109K | |
| 90677 | <1% | 1,095 | $108K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,461 | $105K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,317 | $101K |
| 76820 | <1% | 3,941 | $101K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,576 | $101K |
| 76770 | <1% | 1,278 | $99K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,582 | $99K |
| 83970 | <1% | 3,159 | $98K | |
| 92133 | <1% | 1,931 | $98K | |
| 86900 | <1% | 10,427 | $98K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 10,210 | $95K |
| 76825 | <1% | 577 | $95K | |
| 90686 | <1% | 8,593 | $93K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,539 | $93K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,213 | $92K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 5,789 | $87K |
| 95819 | <1% | 409 | $86K | |
| 82803 | <1% | 10,618 | $86K | |
| 76641 | <1% | 1,813 | $83K | |
| 86359 | <1% | 3,561 | $82K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 348 | $81K |
| 92134 | <1% | 1,516 | $80K | |
| 92083 | <1% | 1,646 | $77K | |
| 83655 | <1% | 5,723 | $77K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,254 | $77K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,864 | $76K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 984 | $76K |
| 87390 | <1% | 4,658 | $76K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,879 | $73K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 572 | $73K |
| 90697 | <1% | 964 | $66K | |
| 92202 | <1% | 1,443 | $65K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 835 | $64K |
| 88248 | <1% | 886 | $64K | |
| 92285 | <1% | 1,205 | $62K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,708 | $61K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,834 | $61K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,811 | $60K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 486 | $60K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,497 | $59K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 46 | $54K |
| 72082 | <1% | 1,332 | $54K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,209 | $53K |
| 86355 | <1% | 2,064 | $53K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 282 | $52K |
| 90670 | <1% | 2,798 | $51K | |
| 80197 | <1% | 7,580 | $50K | |
| 36430 | <1% | 423 | $49K | |
| 81001 | <1% | 15,342 | $49K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 190 | $48K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,752 | $48K |
| 84703 | <1% | 17,067 | $48K | |
| 99381 | <1% | 547 | $48K | |
| 92201 | <1% | 1,161 | $47K | |
| 86803 | <1% | 6,626 | $47K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,032 | $46K |
| Q3014 | Telehealth originating site facility fee | <1% | 2,036 | $43K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 136 | $42K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,999 | $42K |
| 82728 | <1% | 4,731 | $42K | |
| 90715 | <1% | 2,324 | $42K | |
| 83880 | <1% | 3,644 | $41K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,802 | $41K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 789 | $41K |
| 84439 | <1% | 6,404 | $41K | |
| 84702 | <1% | 6,724 | $41K | |
| 93970 | <1% | 306 | $41K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 176 | $40K |
| G0136 | Administration of a standardized, evidence-based assessment of physical activity and nutrition, 5-15 minutes, not more often than every 6 months | <1% | 1,122 | $39K |
| 10060 | <1% | 182 | $38K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 446 | $36K |
| 73564 | <1% | 1,286 | $36K | |
| 86706 | <1% | 5,775 | $36K | |
| 90710 | <1% | 1,546 | $36K | |
| 83020 | <1% | 3,053 | $36K | |
| 86769 | <1% | 1,205 | $35K | |
| 86592 | <1% | 12,119 | $33K | |
| 92579 | <1% | 668 | $33K | |
| 81401 | <1% | 680 | $32K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,113 | $32K |
| 85730 | <1% | 11,275 | $32K | |
| 81003 | <1% | 17,031 | $30K | |
| 82607 | <1% | 3,153 | $30K | |
| 84403 | <1% | 1,328 | $29K | |
| 85027 | <1% | 10,609 | $29K | |
| 66982 | <1% | 15 | $29K | |
| 87340 | <1% | 6,047 | $28K | |
| 88304 | <1% | 1,243 | $27K | |
| 76827 | <1% | 549 | $26K | |
| 82670 | <1% | 1,036 | $26K | |
| 11721 | <1% | 735 | $26K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,938 | $25K |
| 87522 | Neg quan hep c or qual rna | <1% | 795 | $24K |
| 94375 | <1% | 142 | $24K | |
| 82570 | <1% | 6,102 | $24K | |
| 90734 | <1% | 1,180 | $24K | |
| 68810 | <1% | 50 | $24K | |
| 54161 | <1% | 25 | $23K | |
| 90680 | <1% | 2,582 | $23K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 568 | $23K |
| 83735 | <1% | 8,045 | $22K | |
| 80069 | <1% | 2,760 | $21K | |
| 88342 | <1% | 464 | $20K | |
| 94060 | <1% | 268 | $20K | |
| 86762 | <1% | 1,754 | $19K | |
| 84156 | <1% | 6,280 | $19K | |
| 82043 | <1% | 4,702 | $19K | |
| 92588 | <1% | 475 | $19K | |
| 86161 | <1% | 2,083 | $19K | |
| 88142 | <1% | 795 | $18K | |
| 83550 | <1% | 4,774 | $18K | |
| 83001 | <1% | 1,063 | $17K | |
| 51798 | <1% | 81 | $17K | |
| 84146 | <1% | 1,023 | $17K | |
| 73562 | <1% | 1,583 | $17K | |
| 76000 | <1% | 282 | $17K | |
| 83540 | <1% | 4,863 | $17K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $16K |
| 86160 | <1% | 2,094 | $16K | |
| 93325 | <1% | 766 | $16K | |
| 83002 | <1% | 967 | $16K | |
| 90698 | <1% | 2,163 | $16K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,448 | $15K |
| 94729 | <1% | 486 | $15K | |
| 86140 | <1% | 5,134 | $15K | |
| 87806 | <1% | 955 | $15K | |
| 99441 | <1% | 223 | $15K | |
| 73630 | <1% | 1,502 | $14K | |
| 90633 | <1% | 1,946 | $14K | |
| 76775 | <1% | 402 | $14K | |
| 92020 | <1% | 325 | $14K | |
| 83615 | <1% | 3,707 | $14K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 153 | $14K |
| 84100 | <1% | 5,522 | $13K | |
| 90732 | <1% | 364 | $13K | |
| 73030 | <1% | 1,210 | $13K | |
| 97802 | <1% | 182 | $13K | |
| 99173 | <1% | 793 | $13K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 523 | $13K |
| 96415 | <1% | 54 | $12K | |
| 82746 | <1% | 1,516 | $12K | |
| 72100 | <1% | 641 | $12K | |
| 86787 | <1% | 1,950 | $12K | |
| 95812 | <1% | 85 | $12K | |
| 73130 | <1% | 1,082 | $11K | |
| 15731 | <1% | 15 | $11K | |
| 84480 | <1% | 1,884 | $10K | |
| 83605 | <1% | 9,153 | $10K | |
| 85046 | <1% | 5,613 | $10K | |
| 84153 | <1% | 872 | $10K | |
| 84550 | <1% | 3,212 | $10K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 228 | $10K |
| 86704 | <1% | 1,770 | $9K | |
| 73610 | <1% | 1,210 | $9K | |
| 87850 | <1% | 3,033 | $9K | |
| 76813 | <1% | 118 | $9K | |
| 82248 | <1% | 2,110 | $9K | |
| 85652 | <1% | 5,644 | $9K | |
| 86225 | <1% | 1,775 | $8K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,101 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,965 | $8K |
| 94727 | <1% | 328 | $8K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $8K |
| 77080 | <1% | 229 | $8K | |
| 83690 | <1% | 4,904 | $8K | |
| 80076 | <1% | 1,325 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 467 | $7K |
| 82784 | <1% | 629 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 343 | $7K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 173 | $7K |
| 90620 | <1% | 209 | $7K | |
| 86038 | <1% | 1,370 | $7K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 365 | $7K |
| 72141 | <1% | 26 | $7K | |
| 73110 | <1% | 717 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 65 | $6K |
| 86780 | <1% | 1,004 | $6K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 980 | $6K |
| 82105 | <1% | 939 | $6K | |
| 84436 | <1% | 1,934 | $6K | |
| 82950 | <1% | 1,326 | $6K | |
| 84484 | <1% | 6,850 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 85 | $6K |
| 82565 | <1% | 7,820 | $6K | |
| 76536 | <1% | 90 | $6K | |
| 86765 | <1% | 537 | $5K | |
| 86709 | <1% | 976 | $5K | |
| 96127 | <1% | 973 | $5K | |
| 90696 | <1% | 486 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 333 | $5K |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 13 | $5K |
| 94010 | <1% | 163 | $5K | |
| 94760 | <1% | 746 | $5K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 67 | $5K |
| 97803 | <1% | 99 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,444 | $5K |
| 87081 | <1% | 1,240 | $5K | |
| 93350 | <1% | 40 | $5K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,736 | $5K |
| 96376 | <1% | 743 | $4K | |
| 96112 | <1% | 33 | $4K | |
| 82550 | <1% | 1,852 | $4K | |
| 99493 | <1% | 66 | $4K | |
| 86735 | <1% | 527 | $4K | |
| 90744 | <1% | 1,223 | $4K | |
| 73590 | <1% | 601 | $4K | |
| 82652 | <1% | 343 | $4K | |
| 92136 | <1% | 72 | $4K | |
| 83525 | <1% | 363 | $4K | |
| 72170 | <1% | 297 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,176 | $4K |
| 95813 | <1% | 14 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 826 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,470 | $3K |
| 82627 | <1% | 161 | $3K | |
| 73502 | <1% | 213 | $3K | |
| 0011A | <1% | 94 | $3K | |
| 85008 | <1% | 679 | $3K | |
| 90694 | <1% | 248 | $3K | |
| 12001 | <1% | 13 | $3K | |
| J3490 | Unclassified drugs | <1% | 1,201 | $3K |
| 93976 | <1% | 52 | $3K | |
| 88173 | <1% | 70 | $3K | |
| 83883 | <1% | 284 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,183 | $3K |
| 85379 | <1% | 889 | $3K | |
| 93886 | <1% | 14 | $3K | |
| 87517 | <1% | 99 | $2K | |
| 94664 | <1% | 207 | $2K | |
| 90678 | <1% | 42 | $2K | |
| 0012A | <1% | 65 | $2K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 37 | $2K |
| 92225 | <1% | 62 | $2K | |
| 86003 | <1% | 455 | $2K | |
| 98960 | <1% | 64 | $2K | |
| 87070 | <1% | 439 | $2K | |
| 85380 | <1% | 153 | $2K | |
| 84402 | <1% | 87 | $2K | |
| 80074 | <1% | 112 | $2K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 15 | $2K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,010 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,258 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 783 | $2K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 122 | $2K |
| 86832 | <1% | 25 | $2K | |
| 86664 | <1% | 179 | $2K | |
| 72110 | <1% | 56 | $2K | |
| 73140 | <1% | 215 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 912 | $2K |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,487 | $1K |
| 92226 | <1% | 30 | $1K | |
| 99496 | <1% | 12 | $1K | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | <1% | 70 | $1K |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 718 | $1K |
| 87486 | <1% | 85 | $1K | |
| 87040 | <1% | 724 | $1K | |
| 86430 | <1% | 328 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,481 | $1K |
| 70486 | <1% | 13 | $1K | |
| 73090 | <1% | 228 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,890 | $1K |
| 84165 | <1% | 205 | $1K | |
| 73620 | <1% | 169 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,269 | $1K |
| 88307 | <1% | 31 | $1K | |
| 86235 | <1% | 105 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,053 | $1K |
| 90739 | <1% | 24 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,716 | $1K |
| 99201 | <1% | 16 | $1K | |
| 82247 | <1% | 358 | $1K | |
| 83520 | <1% | 115 | $1K | |
| 93923 | <1% | 12 | $1K | |
| 82962 | <1% | 1,210 | $960.83 | |
| 92025 | <1% | 13 | $947.02 | |
| 88300 | <1% | 157 | $935.61 | |
| 86790 | <1% | 145 | $926.91 | |
| 76514 | <1% | 12 | $922.88 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 29 | $876.64 |
| 85007 | <1% | 542 | $868.56 | |
| 86644 | <1% | 105 | $856.43 | |
| 73552 | <1% | 86 | $853.11 | |
| 85384 | <1% | 223 | $837.82 | |
| 93017 | <1% | 28 | $834.70 | |
| 92558 | <1% | 13 | $805.48 | |
| 87581 | <1% | 85 | $787.81 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 58 | $762.09 |
| 90662 | <1% | 50 | $696.57 | |
| 95012 | <1% | 86 | $679.68 | |
| 82785 | <1% | 60 | $677.80 | |
| 86833 | <1% | 13 | $663.85 | |
| 87529 | <1% | 24 | $652.46 | |
| 93290 | <1% | 53 | $639.42 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,670 | $628.93 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,448 | $576.95 |
| 90716 | <1% | 25 | $567.07 | |
| 0240U | <1% | 144 | $538.18 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,915 | $536.76 |
| 90707 | <1% | 24 | $518.24 | |
| 82330 | <1% | 428 | $515.75 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 90 | $491.28 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,568 | $490.68 |
| 76857 | <1% | 15 | $479.12 | |
| 82947 | <1% | 469 | $451.22 | |
| G0270 | Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes | <1% | 17 | $419.92 |
| 84163 | <1% | 32 | $404.26 | |
| 92504 | <1% | 33 | $397.50 | |
| 83498 | <1% | 14 | $395.59 | |
| 82010 | <1% | 597 | $395.51 | |
| 73600 | <1% | 25 | $385.25 | |
| 73080 | <1% | 54 | $373.47 | |
| 77072 | <1% | 24 | $369.62 | |
| 86870 | <1% | 15 | $340.93 | |
| 84132 | <1% | 403 | $339.10 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 12 | $337.38 |
| 84481 | <1% | 38 | $333.95 | |
| 84295 | <1% | 351 | $304.15 | |
| 86304 | <1% | 16 | $277.21 | |
| 86376 | <1% | 19 | $266.44 | |
| J1815 | Injection, insulin, per 5 units | <1% | 125 | $264.40 |
| 86923 | <1% | 12 | $263.19 | |
| 86880 | <1% | 41 | $260.76 | |
| 93280 | <1% | 24 | $254.37 | |
| 82150 | <1% | 89 | $253.76 | |
| 73521 | <1% | 15 | $247.33 | |
| 83516 | <1% | 27 | $227.47 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,922 | $220.48 |
| 85014 | <1% | 307 | $209.30 | |
| 84479 | <1% | 285 | $208.45 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 47 | $208.05 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 169 | $199.14 |
| 73560 | <1% | 27 | $191.37 | |
| 87338 | <1% | 25 | $191.15 | |
| 82435 | <1% | 345 | $189.38 | |
| 90648 | <1% | 122 | $180.99 | |
| 84145 | <1% | 44 | $176.31 | |
| 82533 | <1% | 12 | $167.24 | |
| 86147 | <1% | 15 | $165.73 | |
| 84450 | <1% | 69 | $165.22 | |
| 90700 | <1% | 75 | $161.77 | |
| 86906 | <1% | 14 | $142.48 | |
| 71271 | <1% | 14 | $140.72 | |
| 90687 | <1% | 61 | $139.10 | |
| 90723 | <1% | 17 | $104.57 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 134 | $102.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 651 | $94.72 |
| 73120 | <1% | 29 | $87.32 | |
| 73060 | <1% | 28 | $85.64 | |
| 82951 | <1% | 14 | $82.08 | |
| 86039 | <1% | 13 | $79.90 | |
| 84134 | <1% | 13 | $71.87 | |
| 74018 | <1% | 12 | $70.78 | |
| 86146 | <1% | 14 | $67.45 | |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $42.04 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 85 | $29.91 |
| 82952 | <1% | 17 | $27.90 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 97 | $16.00 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 130 | $15.63 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 13 | $4.94 |
| 91301 | <1% | 123 | $0.10 | |
| 99080 | 0% | 1,976 | $0.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 29 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 23 | $0.00 |
| 95700 | 0% | 12 | $0.00 | |
| 99417 | Prolong home eval add 15m | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, SEAN (SR ASSOCIATE VP/DEPUTY CFO)
| Provider | Location | Paid |
|---|---|---|
| Camden-Clark Physician Corporation | Parkersburg, WV | $19.83M |
| University Hospital of Brooklyn Suny Downstate Health Sciences Univers | Brooklyn, NY | $3.55M |
| University Hospital of Brooklyn Suny Downstate Health Sciences Univers | Brooklyn, NY | $2.19M |
| University Hospital of Brooklyn Suny Downstate Health Sciences Univers | Brooklyn, NY | $953K |
| Compression Therapy Services, INC. | East Lansing, MI | $258.60 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.